Safe imaging agents that are able to render the expression and distribution of cancer
receptors, enzymes or other biomarkers would facilitate clinical screening of the disease …

Purpose To develop a prostate-specific membrane antigen (PSMA)-targeted
radiotherapeutic for metastatic castration-resistant prostate cancer (mCRPC) with optimized …

68Ga-labeled, low-molecular-weight imaging agents that target the prostate-specific
membrane antigen (PSMA) are increasingly used clinically to detect prostate and other …

Expressed on virtually all prostate cancers and their metastases, the transmembrane protein
prostate-specific membrane antigen (PSMA) provides a valuable target for the imaging of …

In an effort to seek novel agents targeting prostate-specific membrane antigen (PSMA), 16
ligands (L1–L16) with structural modifications in S1′ binding pocket were synthesized and …

Despite significant advances in nuclear medicine for diagnosing and treating prostate
cancer (PCa), research into new ligands with increasingly better biological properties is still …

As an element-equivalent theranostic pair, lead-203 (203Pb, 100% EC, half-life= 51.92 h)
and lead-212 (212Pb, 100% β–, half-life= 10.64 h), through the emission of γ rays and an α …

Abstract Technetium-99m (99m Tc) is a radiometal that has nearly ideal nuclear properties
for diagnostic nuclear medicine imaging, which has helped make it high impact and …

Background The overexpression of the chemokine receptor 4 (CXCR4) in different epithelial,
mesenchymal, and hematopoietic cancers makes CXCR4 an attractive diagnostic and …

Introduction Prostate specific membrane antigen (PSMA) is a well-established target for
diagnostic and therapeutic applications for prostate cancer. It is know that [68 Ga] PSMA 11 …